Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
about
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryHistopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case ReportsIncidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials.A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.Methotrexate for the treatment of thyroid eye disease.Comorbidities in Patients with Psoriatic Arthritis.Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan.Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate.Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study.Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.Liver Illness and Psoriatic Patients.
P2860
Q26749054-DE2298F7-4381-4662-B15E-97E1B07C1D71Q33646172-F09AEAB7-C158-4D86-804F-312BBFE26780Q33959573-DB21DEE9-AA5C-4195-BE35-CE54A630EE68Q36417100-2E50873B-1683-45CF-B9C9-B734B342E9CEQ37616156-F3FFE590-2E75-4DD8-B2B6-D6DA160A5CD4Q37632137-BFD0CDC7-868C-481D-990B-C64B3FAA91B9Q37892162-3B4615F0-F007-48B2-85ED-219D63AA954CQ38068540-F66F6C98-FC0B-483C-873E-C579EEC02ACAQ38612446-753A5F86-02D4-4768-B163-11780DE75245Q41312527-D58F9DC9-AF2D-489A-AB3D-AE6AAB1621B1Q44802534-153D4540-B997-4CD9-8B0B-3520ABF027AEQ45325449-05E32C41-A744-4BAB-B3E5-84474671DD28Q52640450-6E849D9B-E049-47F6-A7E4-79C09525966FQ54254957-7675CD67-E94D-4BA9-9843-28D5F59600F0
P2860
Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@en
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@nl
type
label
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@en
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@nl
prefLabel
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@en
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@nl
P50
P356
P1433
P1476
Hepatotoxicity rates do not di ...... sis treated with methotrexate.
@en
P2093
Varda Shalev
P304
P356
10.1093/RHEUMATOLOGY/KEP176
P577
2009-07-03T00:00:00Z